Ascletis Pharma Inc.
ASCLF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$300,936 | -$144,715 | -$314,843 | -$199,017 |
| Dep. & Amort. | $20,454 | $18,480 | $30,191 | $29,545 |
| Deferred Tax | $0 | $0 | $0 | $47,537 |
| Stock-Based Comp. | $3,003 | $1,331 | $3,193 | $7,130 |
| Change in WC | $13,787 | $38,526 | $33,807 | -$10,175 |
| Other Non-Cash | -$77,887 | -$57,784 | $105,199 | -$21,950 |
| Operating Cash Flow | -$341,579 | -$144,162 | -$142,453 | -$146,930 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,095 | -$6,213 | -$14,401 | -$7,198 |
| Net Acquisitions | $0 | $0 | $0 | $2,230 |
| Inv. Purchases | -$637,519 | -$997,222 | -$1,762,400 | -$601,978 |
| Inv. Sales/Matur. | $1,497,433 | $1,166,101 | $479,322 | $332,200 |
| Other Inv. Act. | $121,087 | -$12,821 | $92 | $254 |
| Investing Cash Flow | $978,906 | $149,845 | -$1,297,387 | -$274,492 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$4,733 | -$2,391 | -$2,223 | -$2,284 |
| Stock Issued | $0 | $0 | $961 | $0 |
| Stock Repurch. | -$98,531 | -$78,961 | $0 | -$28,689 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$244 | -$144 | -$157 | -$125 |
| Financing Cash Flow | -$103,508 | -$81,496 | -$1,419 | -$31,098 |
| Forex Effect | $390 | $2,162 | $117,616 | -$30,573 |
| Net Chg. in Cash | $534,209 | -$73,651 | -$1,323,643 | -$483,093 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $330,117 | $403,768 | $1,727,411 | $2,210,504 |
| End Cash | $864,326 | $330,117 | $403,768 | $1,727,411 |
| Free Cash Flow | -$343,727 | -$163,320 | -$156,854 | -$154,128 |